OOIR: Observatory of International Research

Papers

(The TQCC of British Journal of Pharmacology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020	579
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research	320
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors	316
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes	314
Current pharmacological treatments for COVID‐19: What's next?	193
A practical guide for transparent reporting of research on natural products in the British Journal of Pharmacology: Reproducibility of natural product research	177
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets	175
Planning experiments: Updated guidance on experimental design and analysis and their reporting III	170
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels	168
Update of P2X receptor properties and their pharmacology: IUPHAR Review 30	160
Update of P2Y receptor pharmacology: IUPHAR Review 27	149
Animal models of mechanisms of SARS‐CoV‐2 infection and COVID‐19 pathology	149
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors	145
A hypothesis for pathobiology and treatment of COVID‐19: The centrality of ACE1/ACE2 imbalance	142
Arctigenin protects against depression by inhibiting microglial activation and neuroinflammation via HMGB1/TLR4/NF‐κB and TNF‐α/TNFR1/NF‐κB pathways	114
The role of mitochondrial dynamics in cardiovascular diseases	112
Quercetin induces p53‐independent cancer cell death through lysosome activation by the transcription factor EB and Reactive Oxygen Species‐dependent ferroptosis	112
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters	108
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Nuclear hormone receptors	98
Statins: Could an old friend help in the fight against COVID‐19?	97
Berberine protects against diabetic kidney disease via promoting PGC‐1α‐regulated mitochondrial energy homeostasis	87
Community guidelines for GPCR ligand bias: IUPHAR review 32	84
Astaxanthin ameliorates oxidative stress and neuronal apoptosis via SIRT1/NRF2/Prx2/ASK1/p38 after traumatic brain injury in mice	77
Nuciferine protects against folic acid‐induced acute kidney injury by inhibiting ferroptosis	75
The potential of cannabidiol in the COVID‐19 pandemic	75

Non‐steroidal anti‐inflammatory drugs, prostaglandins, and COVID‐19	70
Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitro	69
Cyanidin‐3‐O‐glucoside improves non‐alcoholic fatty liver disease by promoting PINK1‐mediated mitophagy in mice	68
Zebrafish as a tractable model of human cardiovascular disease	68
Unfractionated heparin inhibits live wild type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations	68
Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non‐alcoholic fatty liver disease by up‐regulating the FGF21/PGC‐1α pathway	67
Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease	64
Butyrate ameliorates skeletal muscle atrophy in diabetic nephropathy by enhancing gut barrier function and FFA2‐mediated PI3K/Akt/mTOR signals	64
Potential therapeutic targets and promising drugs for combating SARS‐CoV‐2	64
Anti‐inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H₂S donors in COVID‐19 therapy	60
Leonurine alleviates ferroptosis in cisplatin‐induced acute kidney injury by activating the Nrf2 signalling pathway	59
Sex‐related differences in COVID‐19 lethality	59
A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development: IUPHAR Review 29	58
A rationale for targeting the P2X7 receptor in Coronavirus disease 19	56
Taxane‐induced neurotoxicity: Pathophysiology and therapeutic perspectives	56
Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders	55
Osteosarcoma mechanobiology and therapeutic targets	54
Clinical applications for exosomes: Are we there yet?	54
A systematic review of minor phytocannabinoids with promising neuroprotective potential	52
Eating microRNAs: pharmacological opportunities for cross‐kingdom regulation and implications in host gene and gut microbiota modulation	52
Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it	51
Review of delta‐8‐tetrahydrocannabinol (Δ⁸‐THC): Comparative pharmacology with Δ⁹‐THC	50
Acinar cell NLRP3 inflammasome and gasdermin D (GSDMD) activation mediates pyroptosis and systemic inflammation in acute pancreatitis	49
Oxiapoptophagy: A type of cell death induced by some oxysterols	48
Triptolide prevents LPS‐induced skeletal muscle atrophy via inhibiting NF‐κB/TNF‐α and regulating protein synthesis/degradation pathway	48
Omega‐3 polyunsaturated fatty acids and hypertension: a review of vasodilatory mechanisms of docosahexaenoic acid and eicosapentaenoic acid	48
Identification of endogenous 1‐aminopyrene as a novel mediator of progressive chronic kidney disease via aryl hydrocarbon receptor activation	48
Formyl peptide receptor type 2 agonists to kick‐start resolution pharmacology	47
Inhibition of Bruton's TK regulates macrophage NF‐κB and NLRP3 inflammasome activation in metabolic inflammation	46
Histaminergic neurons in the tuberomammillary nucleus as a control centre for wakefulness	46
Activation of thyroid hormone receptor‐β improved disease activity and metabolism independent of body weight in a mouse model of non‐alcoholic steatohepatitis and fibrosis	46
Adenosine A_2A receptor antagonists: from caffeine to selective non‐xanthines	46
Repositioning PARP inhibitors for SARS‐CoV‐2 infection(COVID‐19); a new multi‐pronged therapy for acute respiratory distress syndrome?	45
Small molecule‐driven SIRT3‐autophagy‐mediated NLRP3 inflammasome inhibition ameliorates inflammatory crosstalk between macrophages and adipocytes	44
Sex‐dependent effects of endocannabinoid modulation of conditioned fear extinction in rats	44
Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment	44
Direct inhibition of the TLR4/MyD88 pathway by geniposide suppresses HIF‐1α‐independent VEGF expression and angiogenesis in hepatocellular carcinoma	43
Inhaled NO and COVID‐19	43
Cardiorenal syndrome: Multi‐organ dysfunction involving the heart, kidney and vasculature	43
Oxysterols: From physiological tuners to pharmacological opportunities	43
Short‐chain fatty acids regulate B cells differentiation via the FFA2 receptor to alleviate rheumatoid arthritis	42
Soluble GC stimulators and activators: Past, present and future	42
Complement, inflammation and thrombosis	40
Metabolic reprogramming by N‐acetyl‐seryl‐aspartyl‐lysyl‐proline protects against diabetic kidney disease	39
Macrophage extracellular traps aggravate iron overload‐related liver ischaemia/reperfusion injury	38
Targeted inhibition of Rev‐erb‐α/β limits ferroptosis to ameliorate folic acid‐induced acute kidney injury	38
STAT3/NF‐κB signalling disruption in M2 tumour‐associated macrophages is a major target of PLGA nanocarriers/PD‐L1 antibody immunomodulatory therapy in breast cancer	37
Human skin models: From healthy to disease‐mimetic systems; characteristics and applications	37
Protective effects of Δ⁹‐tetrahydrocannabinol against enterotoxin‐induced acute respiratory distress syndrome are mediated by modulation of microbiota	36
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders	36

Honokiol ameliorates cisplatin‐induced acute kidney injury via inhibition of mitochondrial fission	35
Signalling, trafficking and glucoregulatory properties of glucagon‐like peptide‐1 receptor agonists exendin‐4 and lixisenatide	35
TLR4 pathway impairs synaptic number and cerebrovascular functions through astrocyte activation following traumatic brain injury	34
The anomalous pharmacology of fentanyl	34
Effects of mavacamten on Ca²⁺ sensitivity of contraction as sarcomere length varied in human myocardium	33
Tetramethylpyrazine: A promising drug for the treatment of pulmonary hypertension	33
LDL receptors, caveolae and cholesterol in endothelial dysfunction: oxLDLs accomplices or victims?	33
Novel drug developmental strategies for treatment‐resistant depression	32
Oxytocin and vasopressin: Signalling, behavioural modulation and potential therapeutic effects	32
Sphingolipid metabolism during Toll‐like receptor 4 (TLR4)‐mediated macrophage activation	32
The STING antagonist H‐151 ameliorates psoriasis via suppression of STING/NF‐κB‐mediated inflammation	32
The development of inhibitors of leucine‐rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play	32
Understanding and countering opioid‐induced respiratory depression	31
Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy	31
Targeting zinc metalloenzymes in coronavirus disease 2019	31
Animal models of pulmonary hypertension: Getting to the heart of the problem	31
Sirtuin 3‐mediated deacetylation of acyl‐CoA synthetase family member 3 by protocatechuic acid attenuates non‐alcoholic fatty liver disease	31
Perspectives for therapy of treatment‐resistant depression	30
Niclosamide—A promising treatment for COVID‐19	30
Cannabidiol improves survival and behavioural co‐morbidities of Dravet syndrome in mice	30
A lesson from a saboteur: High‐MW kininogen impact in coronavirus‐induced disease 2019	30
Tackling COVID‐19 infection through complement‐targeted immunotherapy	30
RNA‐binding motif protein 39 (RBM39): An emerging cancer target	30
Beyond CGRP: The calcitonin peptide family as targets for migraine and pain	30
Targeting α‐synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease	29
Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis	29
Interactions between cannabidiol and Δ⁹‐tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome	29
Mouse models for abdominal aortic aneurysm	29
Role of intracellular complement activation in kidney fibrosis	28
Dysregulation of BMP9/BMPR2/SMAD signalling pathway contributes to pulmonary fibrosis and pulmonary hypertension induced by bleomycin in rats	28
A plant‐derived TRPV3 inhibitor suppresses pain and itch	28
Bletinib ameliorates neutrophilic inflammation and lung injury by inhibiting Src family kinase phosphorylation and activity	28
Protein kinase inhibitors for amyotrophic lateral sclerosis therapy	28
Small interfering RNA: Discovery, pharmacology and clinical development—An introductory review	28
Rhein regulates redox‐mediated activation of NLRP3 inflammasomes in intestinal inflammation through macrophage‐activated crosstalk	28
Therapeutic strategies to fight COVID‐19: Which is the status artis?	27
Fifteen years of Na_V1.7 channels as an analgesic target: Why has excellent in vitro pharmacology not translated into in vivo analgesic efficacy?	27
Restoration of HDAC2 and Nrf2 by andrographolide overcomes corticosteroid resistance in chronic obstructive pulmonary disease	27
Icariside II preconditioning evokes robust neuroprotection against ischaemic stroke, by targeting Nrf2 and the OXPHOS/NF‐κB/ferroptosis pathway	27
Recombinant thrombomodulin protects against LPS‐induced acute respiratory distress syndrome via preservation of pulmonary endothelial glycocalyx	27
The role of glia in the physiology and pharmacology of glucagon‐like peptide‐1: implications for obesity, diabetes, neurodegeneration and glaucoma	27
Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments	27
Structural and molecular determinants of mineralocorticoid receptor signalling	27
1‐Hydroxypyrene mediates renal fibrosis through aryl hydrocarbon receptor signalling pathway	27
The hidden role of NLRP3 inflammasome in obesity‐related COVID‐19 exacerbations: Lessons for drug repurposing	27
The T‐type calcium channel antagonist, Z944, reduces spinal excitability and pain hypersensitivity	26
A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot–Marie–Tooth disease type 1A	26
Strategies towards safer opioid analgesics—A review of old and upcoming targets	26
Post‐translational palmitoylation of ionotropic glutamate receptors in excitatory synaptic functions	26
The 5,6‐epoxycholesterol metabolic pathway in breast cancer: Emergence of new pharmacological targets	26
Targeting TDP‐43 proteinopathy with drugs and drug‐like small molecules	26
N‐acetylcysteine as a new prominent approach for treating psychiatric disorders	25
Effect of selective I_K,ACh inhibition by XAF‐1407 in an equine model of tachypacing‐induced persistent atrial fibrillation	25
Structure‐based discovery of CZL80, a caspase‐1 inhibitor with therapeutic potential for febrile seizures and later enhanced epileptogenic susceptibility	25
KY19382, a novel activator of Wnt/β‐catenin signalling, promotes hair regrowth and hair follicle neogenesis	25
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor	25
Rodent models of hypertension	25
A marine fungus‐derived nitrobenzoyl sesquiterpenoid suppresses receptor activator of NF‐κB ligand‐induced osteoclastogenesis and inflammatory bone destruction	25
Therapeutic validation of an orphan G protein‐coupled receptor: The case of GPR84	25
Nicotinamide adenine dinucleotide metabolism in the immune response, autoimmunity and inflammageing	25
The role of complement in arterial hypertension and hypertensive end organ damage	25
Mice with a specific deficiency of Pfkfb3 in myeloid cells are protected from hypoxia‐induced pulmonary hypertension	25
The therapeutic potential of GLP‐1 receptor biased agonism	24
How environmental enrichment balances out neuroinflammation in chronic pain and comorbid depression and anxiety disorders	24
Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis	24
TRV130 partial agonism and capacity to induce anti‐nociceptive tolerance revealed through reducing available μ‐opioid receptor number	24
Cytokine activin C ameliorates chronic neuropathic pain in peripheral nerve injury rodents by modulating the TRPV1 channel	24
The importance of Ras in drug resistance in cancer	24
Activation of pregnane X receptor induces atherogenic lipids and PCSK9 by a SREBP2‐mediated mechanism	23
CGRP receptor antagonists for migraine. Are they also AMY₁ receptor antagonists?	23
In vitro profiling of orphan G protein coupled receptor (GPCR) constitutive activity	23
Cerebroprotection by dioscin after experimental subarachnoid haemorrhage via inhibiting NLRP3 inflammasome through SIRT1‐dependent pathway	23
Mineralocorticoid receptor in cardiovascular diseases—Clinical trials and mechanistic insights	23
Emerging benefits and drawbacks of α₂‐adrenoceptor agonists in the management of sepsis and critical illness	22
Rho kinase inhibitor fasudil reduces l‐DOPA‐induced dyskinesia in a rat model of Parkinson's disease	22
Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID‐19	22
Enhanced Klotho availability protects against cardiac dysfunction induced by uraemic cardiomyopathy by regulating Ca²⁺ handling	22
Reappraising the role of the vagus nerve in GLP‐1‐mediated regulation of eating	22
Hydrogen sulfide signalling in the CNS ‐ Comparison with NO	22
Emerging therapies and their delivery for treating age‐related macular degeneration	22

NKp30 ‐ A prospective target for new cancer immunotherapy strategies	22
How ACE inhibitors transformed the renin–angiotensin system	22
TLR4 deficiency upregulates TLR9 expression and enhances irinotecan‐related intestinal mucositis and late‐onset diarrhoea	22
Perivascular fat imaging by computed tomography (CT): a virtual guide	22
Palmitoylethanolamide counteracts brain fog improving depressive‐like behaviour in obese mice: Possible role of synaptic plasticity and neurogenesis	22
Populations of in silico myocytes and tissues reveal synergy of multiatrial‐predominant K⁺‐current block in atrial fibrillation	22
Identification and characterization of a novel adiponectin receptor agonist adipo anti‐inflammation agonist and its anti‐inflammatory effects in vitro and in vivo	21
The Concise Guide to PHARMACOLOGY 2023/24: Enzymes	21
Corosolic acid inhibits colorectal cancer cells growth as a novel HER2/HER3 heterodimerization inhibitor	21
Bisphosphonates for delivering drugs to bone	21
PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR	21
Acetylshikonin suppressed growth of colorectal tumour tissue and cells by inhibiting the intracellular kinase, T‐lymphokine‐activated killer cell‐originated protein kinase.	21
Gut microbiota contributes to the development of hypertension in a genetic mouse model of systemic lupus erythematosus	21
Mechanisms of endocannabinoid transport in the brain	21
Uncovering the signalling, structure and function of the 20‐HETE‐GPR75 pairing: Identifying the chemokine CCL5 as a negative regulator of GPR75	21
Inhibition of chemically and mechanically activated Piezo1 channels as a mechanism for ameliorating atherosclerosis with salvianolic acid B	21
Oxoglaucine mediates Ca²⁺ influx and activates autophagy to alleviate osteoarthritis through the TRPV5/calmodulin/CAMK‐II pathway	20
Hypersensitivity to amphetamine's psychomotor and reinforcing effects in serotonin transporter knockout rats: Glutamate in the nucleus accumbens	20
Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra	20
Actions of glucagon‐like peptide‐1 receptor ligands in the gut	20
Role of high‐mobility group box 1 and its modulation by thrombomodulin/thrombin axis in neuropathic and inflammatory pain	20
Multifunctional opioid receptor agonism and antagonism by a novel macrocyclic tetrapeptide prevents reinstatement of morphine‐seeking behaviour	20
The oxysterol receptor GPR183 in inflammatory bowel diseases	20
Metabolic phenotyping of opioid and psychostimulant addiction: A novel approach for biomarker discovery and biochemical understanding of the disorder	20
Administration of all‐trans retinoic acid after experimental traumatic brain injury is brain protective	20
Metformin mitigates gastrointestinal radiotoxicity and radiosensitises P53 mutation colorectal tumours via optimising autophagy	20
Cholesterol and oxysterol sulfates: Pathophysiological roles and analytical challenges	20
Pathophysiological roles of cell surface and extracellular protein disulfide isomerase and their molecular mechanisms	20
Amlodipine, an anti‐hypertensive drug, alleviates non‐alcoholic fatty liver disease by modulating gut microbiota	20
Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1^G93Amice	20
Inhibition of DNA methylation de‐represses peroxisome proliferator‐activated receptor‐γ and attenuates pulmonary fibrosis	20
Macrophage migration inhibitory factor exerts pro‐proliferative and anti‐apoptotic effects via CD74 in murine hepatocellular carcinoma	20
Low‐concentration DMSO accelerates skin wound healing by Akt/mTOR‐mediated cell proliferation and migration in diabetic mice	20
Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics	20
Inhibition of the sodium–glucose co‐transporter SGLT2 by canagliflozin ameliorates diet‐induced obesity by increasing intra‐adipose sympathetic innervation	19
Can rodent models elucidate the pathomechanisms of genetic epilepsy?	19
Inhibition of inflammatory pain and cough by a novel charged sodium channel blocker	19
Regulation of hepatic stellate cell contraction and cirrhotic portal hypertension by Wnt/β‐catenin signalling via interaction with Gli1	19
Brain mineralocorticoid receptor in health and disease: From molecular signalling to cognitive and emotional function	19
5‐hydroxytryptamine in migraine: The puzzling role of ionotropic 5‐HT₃ receptor in the context of established therapeutic effect of metabotropic 5‐HT₁ subtypes	19
Hypoxia‐induced pulmonary hypertension—Utilizing experiments of nature	19
Therapeutic effect of kaempferol on atopic dermatitis by attenuation of T cell activity via interaction with multidrug resistance‐associated protein 1	19
Ruthenium 360 and mitoxantrone inhibit mitochondrial calcium uniporter channel to prevent liver steatosis induced by high‐fat diet	19
Complement in trauma—Traumatised complement?	19
GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets	19
Activation of the MET receptor attenuates doxorubicin‐induced cardiotoxicity in vivo and in vitro	19
Identification of novel therapeutic targets for blocking acantholysis in pemphigus	19
A chalcone derivative, 1m‐6, exhibits atheroprotective effects by increasing cholesterol efflux and reducing inflammation‐induced endothelial dysfunction	19
Time‐dependent dual effect of NLRP3 inflammasome in brain ischaemia	19
Source of dopamine in gastric juice and luminal dopamine‐induced duodenal bicarbonate secretion via apical dopamine D₂ receptors	19
Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis	19
N‐benzhydryl quinuclidine compounds are a potent and Src kinase‐independent inhibitor of NALCN channels	18
Detrimental effects of adolescent escalating low‐dose Δ⁹‐tetrahydrocannabinol leads to a specific bio‐behavioural profile in adult male rats	18
Amitriptyline blocks innate immune responses mediated by toll‐like receptor 4 and IL‐1 receptor: Preclinical and clinical evidence in osteoarthritis and gout	18
The effect of maslinic acid on cognitive dysfunction induced by cholinergic blockade in mice	18
TA₁ agonists attenuate extended‐access cocaine self‐administration and yohimbine‐induced reinstatement of cocaine‐seeking	18
What skeletal muscle has to say in amyotrophic lateral sclerosis: Implications for therapy	18
Glucagon‐like peptide‐1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?	18
Towards a druggable epitranscriptome: Compounds that target RNA modifications in cancer	18
Cough as an adverse effect on inhalation pharmaceutical products	18
A low MW inhibitor of CD44 dimerization for the treatment of glioblastoma	18
Repeated social defeat stress induces neutrophil mobilization in mice: maintenance after cessation of stress and strain‐dependent difference in response	18
Screening for liver X receptor modulators: Where are we and for what use?	18
Oxysterols in cancer management: From therapy to biomarkers	18
The case for chronotherapy in Covid‐19‐induced acute respiratory distress syndrome	18
Endothelium‐derived hydrogen sulfide acts as a hyperpolarizing factor and exerts neuroprotective effects via activation of large‐conductance Ca²⁺‐activated K⁺ channels	18
Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse	18
IL‐17‐induced inflammation modulates the mPGES‐1/PPAR‐γ pathway in monocytes/macrophages	18
Exendin‐4, a GLP‐1 receptor agonist regulates retinal capillary tone and restores microvascular patency after ischaemia–reperfusion injury	18
Increased expression of the ATP‐gated P2X7 receptor reduces responsiveness to anti‐convulsants during status epilepticus in mice	18
Mitophagy: A promising therapeutic target for neuroprotection during ageing and age‐related diseases	18
Cannabinoid control of neurogenic inflammation	18
The application of ‘omics’ to pulmonary arterial hypertension	18
Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35	17
Uncoupling sodium channel dimers restores the phenotype of a pain‐linked Na_v1.7 channel mutation	17
Artesunate interacts with the vitamin D receptor to reverse sepsis‐induced immunosuppression in a mouse model via enhancing autophagy	17
The constitutive androstane receptor and pregnane X receptor in the brain	17
Jumonji domain‐containing protein‐3 (JMJD3) promotes myeloid fibroblast activation and macrophage polarization in kidney fibrosis	17
Harnessing inflammation resolving‐based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID‐19?	17
Heterogeneity in response to repeated intranasal oxytocin in schizophrenia and autism spectrum disorders: A meta‐analysis of variance	17
Characterization of immune checkpoint inhibitor‐induced cardiotoxicity reveals interleukin‐17A as a driver of cardiac dysfunction after anti‐PD‐1 treatment	17
Complement's favourite organelle—Mitochondria?	17
Altered blood–brain barrier and blood–spinal cord barrier dynamics in amyotrophic lateral sclerosis: Impact on medication efficacy and safety	17
Proteinase‐activated receptor 1: A target for repurposing in the treatment of COVID‐19?	17
The selective 5‐HT_1F receptor agonist lasmiditan inhibits trigeminal nociceptive processing: Implications for migraine and cluster headache	17
nNOS‐CAPON blockers produce anxiolytic effects by promoting synaptogenesis in chronic stress‐induced animal models of anxiety	17
Amelioration of elastase‐induced lung emphysema and reversal of pulmonary hypertension by pharmacological iNOS inhibition in mice	17
The role of nucleus of the solitary tract glucagon‐like peptide‐1 and prolactin‐releasing peptide neurons in stress: anatomy, physiology and cellular interactions	17
The canine chronic atrioventricular block model in cardiovascular preclinical drug research	17
Targeting macrophage liver X receptors by hydrogel‐encapsulated T0901317 reduces atherosclerosis without effect on hepatic lipogenesis	17
Sodium rutin extends lifespan and health span in mice including positive impacts on liver health	17
2‐Hydroxypropyl‐β‐cyclodextrin reduces retinal cholesterol in wild‐type and Cyp27a1^−/−Cyp46a1^−/− mice with deficiency in the oxysterol production	17
The VRAC blocker DCPIB directly gates the BK channels and increases intracellular Ca²⁺ in melanoma and pancreatic duct adenocarcinoma cell lines	17
Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity	17
Phytocannabinoid‐dependent mTORC1 regulation is dependent upon inositol polyphosphate multikinase activity	17